LG Chem Life Sciences

LG Chem Life Sciences is the biopharmaceutical division of LG Chem, a leading global chemical company headquartered in South Korea. The company focuses on the development, manufacturing, and commercialization of a diverse portfolio of products across oncology, immunology, and metabolic diseases. Key commercial products include Zemiglo (gemigliptin) for type 2 diabetes and Eutropin for growth hormone deficiency. In early 2023, the company significantly expanded its global oncology footprint through the acquisition of Aveo Oncology, integrating the commercial-stage drug Fotivda into its portfolio. LG Chem Life Sciences maintains a robust R&D pipeline, including the Phase 3 gout candidate tigulixostat, and operates a major innovation center in Boston to drive global clinical development. The division leverages its parent company's manufacturing excellence to produce high-quality biologics and small molecules for global markets.